Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05147142Not ApplicableActive Not Recruiting

Low Intensity Focused Ultrasound: a New Paradigm for Depression and Anxiety

Role: lead

NCT06957067Not ApplicableRecruiting

Reducing Dropout and Improving Outcomes From PTSD Therapy: When to Switch Therapies or Stay the Course

Role: collaborator

NCT05110313Phase 4Completed

Effects of Tildrakizumab on Epigenetic Age

Role: collaborator

NCT03441867Not ApplicableUnknown

Neuroimaging Biomarker for Seizures

Role: collaborator

All 4 trials loaded